Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (filo)

Sophie Godet; Caroline Protin; Jehan Dupuis; Caroline Dartigeas; Jean‐noël Bastie; Charles Herbaux; Véronique Leblond; Sophie de Guibert; David Ghez; Annie Brion; Loïc Ysebaert; Alain Delmer; Anne Quinquenel

doi:10.1002/ajh.24981

DOI: 10.1002/ajh.24981

,

PMID: 29164674

Issn Print: 0361-8609

Publication Date: 2018/02/01

Print

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Sophie Godet; Caroline Protin; Jehan Dupuis; Caroline Dartigeas; Jean‐Noël Bastie; Charles Herbaux; Véronique Leblond; Sophie de Guibert; David Ghez; Annie Brion; Loïc Ysebaert; Alain Delmer; Anne Quinquenel

+ Author Information

Author Information: CHU Reims, Hôpital Robert Debré, Service d'Hématologie Clinique


		Checking for direct PDF access through Ovid

View on Journal Site

Abstract

Abstract unavailable for this article.


		Loading Related Articles